CHP
TBPH icon

Cable Hill Partners’s Theravance Biopharma TBPH Stock Holding History

Cable Hill Partners’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-66
Closed -$1K – 759
2015
Q2 		$1K Hold
66
– – ﹤0.01% 702
2015
Q1 		$1K Buy
66
+22
+50% +$403 ﹤0.01% 701
2014
Q4 		$1K Buy
+44
New +$767 ﹤0.01% 684

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FAM
Foundation Asset Management White Plains, New York $116M AUM 31.02% 1-Year Est. Return

Cable Hill Partners's TBPH Position: Q3 2015 in Review

Cable Hill Partners sold out of Theravance Biopharma (TBPH) in Q3 2015, closing a stake of 66 shares — an estimated $1K sold.

Cable Hill Partners first reported a position in TBPH in Q4 2014 and held it in 3 quarters. The position peaked at $1K in Q2 2015. 83 funds tracked by Wall St. Rank hold TBPH as of Q3 2015.

  • Cable Hill Partners reported no remaining Theravance Biopharma position as of Q3 2015 after selling out during the quarter.
  • Cable Hill Partners sold 66 Theravance Biopharma shares in Q3 2015, an estimated $1K.
  • Cable Hill Partners first reported a position in Theravance Biopharma in Q4 2014 and held it in 3 quarters.
  • Cable Hill Partners's Theravance Biopharma position peaked at $1K in Q2 2015.
  • 83 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2015.

Based on Cable Hill Partners's 13F filing for Q3 2015, filed 4 Aug 2016.